Laborie Acquires JADA System in Landmark Deal to Combat Maternal Mortality

PORTSMOUTH, NH – January 28, 2026 – Laborie Medical Technologies has finalized its acquisition of the JADA® System, an innovative device for treating postpartum hemorrhage, in a deal valued at up to $465 million. The move signals a major strategic investment in maternal health, positioning Laborie to tackle one of the most persistent and tragic challenges in childbirth.

The acquisition brings the FDA-cleared JADA System, previously owned by Organon, into Laborie’s expanding obstetrics portfolio. This transaction underscores a growing focus within the medical technology industry on developing and scaling solutions for postpartum hemorrhage (PPH), the leading cause of maternal death worldwide.

A New Weapon Against a Global Killer

Postpartum hemorrhage is a sudden and often catastrophic complication of childbirth, defined as excessive bleeding after delivery. According to the World Health Organization, PPH is responsible for more than 20% of all maternal deaths globally, claiming the lives of tens of thousands of women each year and causing severe, life-altering complications for millions more. The most common cause, accounting for roughly 80% of cases, is uterine atony, a condition where the uterus fails to contract effectively after birth, leaving blood vessels exposed and bleeding.

For decades, clinicians have relied on a sequence of interventions, from uterotonic drugs to manual massage, and invasive procedures like uterine balloon tamponades or, in the most dire circumstances, emergency hysterectomy. While often effective, these methods can be slow to act or carry significant risks. It is in this high-stakes environment, where every second is critical, that the JADA System has emerged as a groundbreaking alternative.

"The JADA System helps care teams provide treatment during one of the most vulnerable moments of childbirth when every second counts," said Nikki Bruce, Laborie's Vice President and General Manager of OB, in a statement announcing the deal. "The mission of our Laborie OB business unit has always been to help every mother and newborn go home healthy."

How Innovation Meets Physiology

Unlike traditional methods that rely on applying internal pressure, the JADA System utilizes a novel approach: vacuum-induced uterine contraction. The device consists of a soft, flexible silicone loop that is inserted into the uterus. Once in place, it is connected to a low-level vacuum source. This gentle negative pressure encourages the uterus to contract naturally and firmly, mimicking the body's own physiological response to stop bleeding.

This mechanism offers a key advantage: speed. Clinical data has shown that the device can control hemorrhage in a matter of minutes, a critical factor in preventing the cascade of complications that can lead to maternal mortality, such as shock, organ failure, and the need for massive blood transfusions.

The clinical evidence backing the device is substantial. Its FDA clearance in 2020 was supported by the pivotal PEARLE IDE study, which demonstrated a remarkable 94% success rate in controlling bleeding, with a median time to hemorrhage control of just three minutes. A subsequent, larger real-world study published in 2023 involving 800 patients across 16 U.S. hospitals reinforced these findings, showing success rates of 92.5% for vaginal births and 83.7% for cesarean births. In that study, bleeding was controlled within five minutes for the majority of patients.

A Strategic Play in Maternal Health

The acquisition is a significant strategic move for Laborie, a global medical technology company with a diverse portfolio in urology, gastroenterology, and neonatal health. The deal, valued at $440 million upfront with a potential for an additional $25 million, represents a substantial bet on the JADA System's potential. Organon, which acquired the device in 2021 for an initial $219 million, saw its sales triple to $61 million by 2024, with the device stocked in 94% of the largest U.S. birthing hospitals, indicating strong market acceptance and a clear trajectory of growth.

For Laborie, the JADA System is more than just a new product; it's a cornerstone for its maternal health division. The acquisition aligns with a history of strategic growth, supported by its parent company, Patricia Industries.

"The addition of the JADA System and the incredible team behind it marks a tremendous milestone for our OB business and an exciting chapter in Laborie's history," stated Laborie President and CEO Chris Smith. "This step forward aligns perfectly with our company's dedication to elevating the standard of care for clinicians and patients."

The move also brings over 90 new employees, primarily in commercial roles, from Organon to Laborie, ensuring a continuity of expertise and market momentum. This integration will be crucial as Laborie seeks to expand the JADA System's reach beyond the U.S. and into global markets where the need for effective PPH solutions is even more acute.

This acquisition is not merely a transaction but a reflection of a broader commitment to long-term value creation that extends to societal benefit, a principle championed by Laborie's ownership. "This transaction reflects Patricia Industries' commitment to growing our platform companies through acquisitions that enable them to pursue their inspirational missions while enhancing their portfolio innovation and long-term profitable growth," commented Yuriy Prilutskiy, Co-Head of Patricia Industries. With its proven efficacy and now the backing of a major global medical technology firm, the JADA System is poised to play an even greater role in the worldwide effort to make childbirth safer for every mother.